Human embryonic lung (HEL) cells infected with human cytomegalovirus (HCMV) restricted the replication of herpes simplex virus type 1 (HSV-1). A delay in HSV replication of 15 h as well as a consistent, almost 3 log inhibition of HSV replication in HCMV-infected cell cultures harvested 24 to 72 h after superinfection were observed compared with controls infected with HSV alone. Treatment of HCMV-infected HEL cells with cycloheximide (100 ,ug/mI) Human cytomegalovirus (HCMV) and herpes simplex virus (HSV) are members of the family Herpesviridae, but are nevertheless biologically and biochemically distinct (35, 36) . HCMV has a high species specificity, limited host range, and long replicative cycle compared with HSV, which has a low species specificity, wide host range, and relatively short replicative cycle. Limited sequence homology has been detected between the HCMV genome (240 kilobase pairs), and the HSV genome (150 kilobase pairs) (10, 20, 23) . Despite this lack of sequence homology, the HCMV and HSV genomes are structurally similar and both viruses are capable of establishing latent infections in human cells (4, 24, 34, 43, 48) .
Human cytomegalovirus (HCMV) and herpes simplex virus (HSV) are members of the family Herpesviridae, but are nevertheless biologically and biochemically distinct (35, 36) . HCMV has a high species specificity, limited host range, and long replicative cycle compared with HSV, which has a low species specificity, wide host range, and relatively short replicative cycle. Limited sequence homology has been detected between the HCMV genome (240 kilobase pairs), and the HSV genome (150 kilobase pairs) (10, 20, 23) . Despite this lack of sequence homology, the HCMV and HSV genomes are structurally similar and both viruses are capable of establishing latent infections in human cells (4, 24, 34, 43, 48) .
Immunocompetent human hosts may harbor several latent viruses without clinically apparent effects, whereas humans who are immunocompromised as a result of cancer therapy, acquired immunodeficiency syndrome, or transplant surgery are clinically at risk for severe systemic disease associated with reactivation of latent viruses (14, 15, 29) . Herpesviruses, in particular, often reactivate simultaneously in immunocompromised hosts, presenting the problem of multiple clinical viral infections (29) .
The role of HCMV in virus-virus interactions within host cells has been the subject of intense investigation in the last few years. Colberg-Poley and co-workers (8) demonstrated the involvement of an early function of HCMV in reactivation of latent HSV in vitro. Everett (12) described the ability of cloned immediate-early (IE) HCMV and pseudorabies virus gene products to activate transcription from an HSV type 1 (HSV-1) early promoter. Tevethia and Spector (42) described the ability of HCMV to act as a transcriptional activator capable of functionally substituting for the Ela sequences of adenovirus type 5. Recently, HCMV was shown to complement the naturally defective human parvovirus, adeno-associated virus (28) . In addition to complementation of other virus genomes, HCMV also has the ability to interfere with the replication of other viruses. As reported recently by Spaete and Mocarski (39) , substitution of the HCMV a sequence for the HSV cleavage-packaging signal on a chimeric amplicon resulted in cleavage and packaging of HSV-1 defective genomes. In addition, Figueroa et al. (13) reported the resistance of HCMV-transformed cells to superinfection with HSV.
This report presents a study on viral interactions between HCMV and HSV during productive infection of human embryonic lung (HEL) cells in vitro. We observed that an HCMV function expressed during infection of HEL cells inhibited replication of superinfecting HSV.
MATERIALS AND METHODS
Cell culture and virus. HEL cell cultures were maintained as previously reported (4 Infectious center assays. Mock-superinfected or HSV-superinfected cultures treated or not treated with cycloheximide (100 ,ugIml) were analyzed by the infectious center assay in HEL cells. HCMV-infected cultures were washed three times with Tris-buffered saline (TBS; pH 7.3) and then were mock infected or superinfected with HSV. At 3 hours after superinfection, cultures were washed twice with EDTA and then trypsinized with 1 ml of trypsin per culture. After trypsinization, 1 ml of maintenance medium was added to each culture to a total volume of 2 ml. Cell counts were then performed, and 0.2-ml samples from superinfected cell cultures were assayed in Vero cell monolayers overlaid with methylcellulose. After 5 to 7 days at 37°C, cultures were stained with crystal violet and the number of infectious centers per culture was determined.
Sera. HCMV antibody-positive (EM6) and antibody-negative (MJT) sera were characterized and supplied by M. J. Tevethia (The Pennsylvania State University College of Medicine).
Immunoprecipitation and polyacrylamide gel electrophoresis. HEL cells were mock infected or infected with HCMV at a multiplicity of infection of 3.0 PFU per cell, virus was allowed to adsorb for 1 h, and cultures were then treated with medium alone or medium containing cycloheximide (100 ,ug/ml) for 3 or 24 h. After treatment, cultures were washed twice with EDTA, labeled with [35S]methionine (50 ,uCi/ml) for 2 h, precleared with normal hamster serum (50 pI) , and immunoprecipitated with HCMV antibody-positive or -negative polyvalent sera with Sepharose A beads, according to the protocol described by Kessler (22) . The immunoprecipitated polypeptides were then separated by electrophoresis on a 12.5% polyacrylamide gel by the method of Laemmli (25) . After electrophoresis, gels were fixed for 1 h in 5% trichloroacetic acid, processed for fluorography (3), and exposed on Kodak XL-1 film for 3 weeks at -70°C. [methyl-'4C]polypeptide molecular weight standards consisted of phosphorylase b, 97,400; bovine serum albumin, 69,000; ovalbumin, 46,000; carbonic anhydrase, 30,000; lactoglobulin A, 18,400; and cytochrome c, 12,300.
Preparation of purified 3H-labeled HSV-1. Vero cells were infected with 10 to 20 PFU of HSV-1 per cell. At 6 hours postinfection (p.i.), cells were labeled with [3H]thymidine (10 1xCi/ml), and after labeling, infected cells were frozen and thawed three times to release virus. 3H-labeled HSV was then precipitated with 0.05 M zinc-acetate by the procedure of Sokol et al. (38) . 3H-labeled HSV was suspended in EDTA, and subjected to cesium chloride density gradient centrifugation, and the infectious virus band was collected (M. K. Howett, personal communication).
Isolation of nuclear and cytoplasmic fractions from superinfected cells. Monolayers of HEL cells (35-mm plates) were exposed to 3.0 PFU of HCMV per cell for 1 h and then were superinfected with purified 3H-labeled HSV-1 (2.0 PFU per cell; 200,000 cpm per plate). After a 1-h adsorption period, nonadsorbed 3H-labeled HSV-1 was removed, and superinfected cultures were washed with TBS and then overlaid with maintenance medium. At time points 1 to 20 h after superinfection, cultures were harvested as described above. Medium was removed, and cells were washed with TBS, scraped into 1 ml of TBS, and sedimented at 10,400 x g for 10 min in a Sorvall refrigerated (4°C) centrifuge. After centrifugation, the supernatant was removed and the pellet was suspended in 0.5 ml of isotonic buffer containing 0.5% Nonidet P-40 and left on ice with occasional shaking for 10 min, and then nuclei were sedimented in an Eppendorf centrifuge at 4°C for 5 min. After sedimentation, the supernatant containing the cytoplasmic fraction was removed and the pellet containing the nuclear fraction was resuspended in 0.5 ml of Nonidet P-40 isotonic buffer. Trichloroacetic acid-precipitable counts from 5-,ul samples were then determined in nuclear and cytoplasmic fractions after three trichloroacetic acid (5%), two ethanol (95%), and one acetone wash of the dried Whatman filter paper disks.
Cesium chloride density gradient centrifugation of DNA. Nuclear fractions (200 pLl, -10,000 cpm) obtained from 3H-labeled HSV superinfection experiments (3 h p.i.) were combined with 14C-labeled TC-7 cell DNA (8.5 pLl, -5,000 cpm), 5.0x STEP buffer (50 mM Tris hydrochloride [pH 7.51-40 mM EDTA), sodium dodecyl sulfate (0.5%), and proteinase K (2 mg/ml) to a final volume of 1 ml. Samples then were digested at 50°C for 1 h. After digestion, the 1-ml labeled sample was added to 3 ml of cesium chloride solution in 0.1 x SSC (1 x SSC is 0.15 M NaCl plus 0.015 M sodium citrate) (final density of gradient, 1.71 g/ml) and centrifuged at 33,000 rpm for 60 h with a 40.30 fixed-angle rotor (19) . After centrifugation, 8-drop fractions (-0.1 ml) were collected and 50-pul samples were assayed for trichloroacetic acid-precipitable counts on Whatman filter paper disks.
Detection by blot hybridization of HSV-1 DNA synthesized in HCMV-infected HEL cells. HEL cells were mock infected or HCMV infected (3.0 PFU per cell). At 24 h p.i., cultures were mock superinfected or HSV-1 superinfected (0.01 or 3.0 PFU per cell). At times 0 to 1 h and 48 h after superinfection, DNA was extracted from cells as previously described (49) with several modifications. The cells were harvested by scraping into EDTA (pH 7.4) and centrifuged at 10,400 x g for 10 min. The pellets were washed once in TBS (pH 7.4), suspended in 10 ml of TNE (10 mM Tris hydrochloride [pH 8 .0]-15 mM NaCl-10 mM EDTA)-0.2% sodium dodecyl sulfate-100 mg of proteinase K per ml. The lysate was incubated at 37°C for 12 h, extracted with TNEsaturated phenol-chloroform, and precipitated in 2 volumes of 95% ethanol in the presence of 0.2 M sodium acetate at -20°C overnight. The precipitated DNA was centrifuged at 17,369 x g for 30 min, the supernatant was discarded, and pellets were suspended in 5 ml of 1 x TE (10 mM Tris hydrochloride [pH 8 .0]-1 mM EDTA). RNase A treatment (100 mg/ml) was then done at 37°C for 1 h, followed by a final ethanol precipitation.
Extracted DNA (5 pug/20 pul of 1 x TE) was spotted onto nitrocellulose (17) , denatured for 20 min in 0.5 M NaOH-1.5 M NaCl, and neutralized in 0.2 M Tris hydrochloride-0.03 M NaCl-3 mM sodium citrate. The blot was air dried and baked in a vacuum oven at 80°C for 1.5 h. The blotted DNA was hybridized (44) to the nick-translated in vitro 32P-labeled EcoRI A fragment of HSV-1 cloned into the pACYC184 vector (6) (27) of the protocol designed by Rigby et al. (33) . The reaction mixture was described previously (7) . Specific activities of 3 x 108 to 4 x 10' cpm/4g of DNA were achieved. Controls including pACYC184 (6) vector DNA and HEL cell DNA (provided by Brian Wigdahl) as well as a reconstruction mixture (20 p.l) composed of HEL cell DNA (10 jig) in the presence of HSV-1 virion DNA in decreasing quantities (1 to 0 ,ug) were blotted onto nitrocellulose. The HSV-1 virion DNA was extracted from HEL cells infected with HSV-1 (1.0 PFU per cell) as described by Sokol et al. (38) and adapted by M. K. Howett (personal communication). The visible virus band collected from a cesium chloride step gradient (1.2 to 1.4 g/ml) was digested for 1 h at 37°C with proteinase K (2 mglml)-0. 1% sodium dodecyl sulfate-10 mM Tris hydrochloride-8 mM EDTA, phenol-chloroform extracted, ethanol precipitated, and suspended in lx TE.
Superinfection of HCMV-infected HEL cells. Confluent monolayers of HEL cells were mock infected or infected with 3.0 PFU of HCMV per cell, virus was allowed to adsorb for 1 h, virus inoculum was removed, and the cultures were washed with TBS and overlaid with medium alone or medium containing cycloheximide (100 ,ug/ml) for 24 h. After cycloheximide treatment, cultures were washed three times with TBS and infected with 0.01 to 0.10 PFU of HSV per cell. The superinfected cultures were washed twice with EDTA and harvested for infectious center assay after 3 h or for plaque assay after 24 h.
RESULTS
Inhibition of HSV-1 replication was demonstrated in HEL cells infected with 3.0 PFU of HCMV per cell and then superinfected with 0.01 PFU of HSV per cell at various times after infection. Infectious center assays were performed 3 h after superinfection; 7 days later, the number of infectious centers per culture was determined ( Table 1 ). The number of HSV infectious centers detected was diminished in HCMV-infected HEL cell cultures in comparison with that in mock cultures infected with HSV alone. The percent decrease in HSV activity was greatest in HEL cells infected with HCMV 24 h before HSV superinfection, but was readily apparent even 1 h after HCMV infection.
Immunoprecipitation was used to determine whether cycloheximide treatment (100 ,ug/ml), a condition previously Table 2 , footnote b). Removal of the cycloheximide block after 6 or 24 h followed by HSV superinfection resulted in an additional reduction (approximately 90%) in the number of HSV-1 infectious centers compared with that in cycloheximide-treated cultures not infected with HCMV. Processing of the accumulated HCMV IE and E mRNA after removal of the cycloheximide block appeared to enhance the HCMV-associated restriction of superinfected HSV.
Enhanced inhibition of HSV-1 replication after cycloheximide-induced accumulation of HCMV gene products in HCMV-infected cells was also detected in plaque assays of cell-free virus obtained from superinfected cultures (Table  3) . HEL cells infected with HCMV (3.0 PFU per cell) were incubated at 37°C with medium containing cycloheximide (100 ,g/ml) or medium alone for 24 h. Cultures were then washed with TBS and superinfected with HSV-1 (0.01 PFU per cell). After 24 h, the superinfected cultures were harvested by three cycles of freezing and thawing. Although cycloheximide treatment did result in a reduction in the virus titer in cells infected with HSV alone, HSV was undetect- (Fig. 2) . Results demonstrated a delay of up to 15 h in HSV-1 replication in HCMV-infected cultures compared with that in mock-infected cultures infected with HSV-1 alone, which displayed an 8-to 10-h delay between adsorption and appearance of newly replicated infectious HSV. In addition, cultures harvested at times greater than 24 h after superinfection displayed a consistent, almost threefold difference in the titer of HSV-1 in mock-infected versus HCMV-infected HEL cells.
3H-labeled HSV-1 (0.2 ml = 200,000 cpm per plate) was used to superinfect HCMV-infected HEL cells to determine whether HSV could enter and penetrate the nucleus. The labeled HSV-1, after concentration, had a titer of 7.5 x 109 PFU/ml. The data (Table 5) tion (final density, 1.71 g/ml) against "4C-labeled TC-7 cell DNA, clear separation between viral and cellular DNA peaks was evident (Fig. 3) . The presence of a single peak which bands at the density of virus DNA (1.72 gIml) provides evidence of the penetration of superinfecting HSV into the nucleus of HCMV-infected cells and argues against reutilization of the 3H label, which also would have been reincorporated into and visualized as a 3H peak banding at the density of cell DNA (1.69 g/ml).
Blot hybridization of the HSV-1 DNA synthesized in superinfected cell cultures provided additional evidence to counts per minute inoculated. c A decrease in total counts per minute recovered at harvest times greater than 1 h p.i. was attributed to nonspecific as well as virus-specific degeneration of cells, which were removed when maintenance medium was removed before harvesting infected cells. (Fig. 4) , previously demonstrated to lack sequence homology with human DNA (21) . Hybridization results (Fig.  5) To determine the specificity of the inhibition associated with HSV-1 superinfection in the HEL system, we studied a number of viruses. When HSV type 2 (HSV-2) (0.1 PFU per cell) was used first as a superinfecting virus, it appeared to be restricted in HCMV-infected HEL cells in a manner similar to that observed for HSV-1, both in the presence and in the absence of cycloheximide (data not shown). Replication of superinfecting adenovirus (another DNA virus) in HCMV-infected HEL cells was not inhibited, even in the presence of cycloheximide at 24 h p.i. which is well into the late phase of adenovirus infection (42) . HEL cells infected with HCMV (3.0 PFU per cell) and incubated for 24 h in the presence or absence of cycloheximide were superinfected with adenovirus (0.01 PFU per cell). When cultures were assayed for infectious virus in 293 cells (16) , the titer of adenovirus remained constant in all cultures regardless of the presence of HCMV or cycloheximide or both (data not shown).
In an attempt to demonstrate that interferon was not associated with the restriction observed, we used VSV, an RNA virus that is highly susceptible to the antiviral effects of interferon, to superinfect HCMV-infected HEL cells. HEL cells treated with cycloheximide nor those not treated were capable of restricting the number of VSV infectious centers produced compared with that in control cultures (Table 6) . Additional experiments have shown that enhancement in the levels of VSV replication in HCMV-infected cells (Table 6) does not appear to be significant (data not shown). In addition, control cultures pretreated with human alpha interferon (300 IU/ml) for 24 (8, 48) . The observation that HCMV may have both positive and negative regulatory effects on HSV may be relevant in vivo considering the ubiquity of these viruses and their simultaneous existence within a human host (29) . However, this phenomenon may prove difficult to understand considering the questions yet to be answered concerning herpesvirus latency, coinfection of cells with herpesviruses, and regulation of herpesvirus replication, both in vivo and in vitro. Several mechanisms have previously been associated with the restriction of HSV replication in vitro including (i) impaired penetration of virus into infected cells; (ii) restricted viral DNA synthesis; (iii) ineffective products specified by viral DNA; and (iv) impaired assembly and/or envelopment of virus progeny (1, 5, 11, 26) . The restriction of HSV observed in our laboratory appears to be associated with expression of either an HCMV IE or E gene product or an HCMV-induced host gene product in HCMV-infected cells. Restriction of HSV did not occur in HEL cells infected with UV-irradiated, functionally inactivated HCMV (Table  7) . Conditions which allowed accumulation of HCMV IE and E gene products (31) in cycloheximide-treated HCMVinfected cells produced an additive effect which resulted in enhanced restriction of superinfected HSV (Tables 2 and 3) . These results (Tables 2 and 3 ) implied a role for events occurring early in the HCMV life cycle in the inhibition of HSV.
In addition, HCMV DNA-negative ts mutants which express IE and E viral gene products at the nonpermissive temperature (39.5°C) inhibited HSV replication in superinfected cells at least as well as wild-type HCMV ( Table 4 ), suggesting that HCMV DNA synthesis and the events which precede it are not necessary to restrict HSV. Results obtained from a growth curve of HSV-1 generated in HCMVinfected HEL cells (Fig. 2 ) demonstrated a consistent restriction of HSV in superinfected cells compared with cell cultures infected with HSV alone. At time points after 24 h, there was a compounded, nearly threefold difference in HSV titer in the mock-infected versus HCMV-infected cells. The results obtained from blot hybridizations (Fig. 5) , which demonstrate qualitatively similar levels of HSV DNA synthesis in mock-infected versus HCMV-infected cells, suggest that HCMV-infected HEL cells do not impede the penetration of superinfecting HSV. Detection of 3H-labeled HSV in the nuclei of superinfected cells (Table 5 ) and isolation of 3H-labeled virus DNA from the nuclei of superinfected cells 2 h after superinfection (Fig. 3 ) also provide evidence to support penetration of HSV into superinfected cell nuclei. These data define the phenomenon of restriction of superinfecting HSV by an HCMV-encoded and/or HCMV-induced product which appears to result from a block in the HSV replication cycle after virus adsorption. Rouse et al. (37) previously demonstrated the inhibition of plaque production by adenovirus in monolayers of human cells resulting from an arginine deficiency induced by contamination of human cell cultures with pleuropneumonia-like organisms (PPLO). Elimination of PPLO, which alleviates the inefficient production of adenovirus plaques, was later demonstrated to occur after treatment of cell cultures with the antibiotic kanamycin (30) . Routine kanamycin treatment as well as PPLO testing of human cell cultures ruled out the role of PPLO in the inhibition of HSV replication in our system.
Although we currently lack sufficient information to understand the molecular basis for the inhibition of HSV replication by HCMV, we gained some insight into the nature of the phenomenon. Obliteration of the inhibition phenomenon by UV irradiation of HCMV indicated that either a functional HCMV genome or an HCMV virion structural component is required to block HSV replication (18) . Inhibition of HSV in HCMV ts mutant (51) 48 h, despite the difference in the levels of infectious HSV detected by plaque assay at 48 h (Fig. 2 ), suggests that a block which occurs late in the HSV replication cycle after viral DNA synthesis may be responsible for the restriction of HSV.
HCMV-infected HEL cells, which inhibit replication of superinfected HSV, provide an efficient system in which to investigate the exact HCMV gene function responsible for inhibition of HSV. Analysis of HCMV mRNA present after cycloheximide treatment can now be utilized to define further the HCMV genome segment encoding the inhibitory function. The point at which HSV is restricted also needs further examination. Analysis of virus proteins should provide information on the molecular events regulating inhibition of HSV by HCMV.
